Synthesis and anti-breast cancer activities of substituted quinolines

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 11, 2008, Pages 3364-3368

  Shi, Aibin ^a   Nguyen, Thu A ^a   Battina, Srinivas K ^a   Rana, Sandeep ^a   Takemoto, Dolores J ^a   Chiang, Peter K ^b,c   Hua, Duy H ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Pharmadyn Inc   (United States)

Author keywords

Anti breast cancer agents; Synthesis of substituted quinolines; T47D breast cancer cells

Indexed keywords

6 METHOXY 4 METHYL 8 NITRO 5 (3 TRIFLUOROMETHYLPHENYLOXY)QUINOLINE; 6 METHOXY 8 [(2 FURANYLMETHYL)AMINO] 4 METHYL 5 (3 TRIFLUOROMETHYLPHENYLOXY)QUINOLINE; 8 AMINO 6 METHOXY 4 METHYL 5 (3 TRIFLUOROMETHYLPHENYLOXY)QUINOLINE; ANTINEOPLASTIC AGENT;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MICHAEL ADDITION;

BREAST NEOPLASMS; COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLIZATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44349165109     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.024     Document Type: Article

References (20)

1. LaMontagne M.P., Markovac A., and Khan M.S. J. Med. Chem. 25 (1982) 964
2. LaMontagne M.P., Blumbergs P., and Strube R.E. J. Med. Chem. 25 (1982) 1094
3. Wiesner J., Ortmann R., Jomaa H., and Schlitzer M. Angew. Chem., Int. Ed. 42 (2003) 5274
4. Dade J., Provot O., Moskowitz H., Mayrargue J., and Prina E. Chem. Pharm. Bull. 49 (2001) 480
5. Veyssier P., and Bryskier A. Antimicrob. Agents (2005) 941
6. Cnubben N.H.P., Wortelboer H.M., van Zanden J.J., Rietjens I.M.C.M., and van Bladeren P.J. Expert Opin. Drug Metab. & Toxicol. 1 (2005) 219
7. Boyle R.G., and Travers S. Anti-Cancer Agents Med. Chem. 6 (2006) 281
8. Kawase M., and Motohashi N. Curr. Drug Targets 4 (2003) 31
9. Levitt M.L., and Koty P.P. Invest. New Drugs 17 (1999) 213
10. Lauer W.M., Rondestvedt C., Arnold R.T., Drake N.L., van Hook J., and Tinker J. J. Am. Chem. Soc. 68 (1946) 1546
11. von Dieter. Sicker E.s., and Wilde H. Helv. Chim. Acta 79 (1996) 658
12. Kaji E., and Zen S. Bull. Chem. Soc. Japan 46 (1973) 337
13. Butskus P.F. Zhurnal Obshchei Khimii 31 (1961) 764
14. Klenke B., Stewart M., Barrett M.P., Brun R., and Gilbert I.H. J. Med. Chem. 44 (2001) 3440
15. McElvain S.M., and Nelson J.W. J. Am. Chem. Soc. 64 (1942) 1825
16. Easson A.P.T., and Pyman F.L. J. Chem. Soc. (1931) 2991
17. Borch R.F., Bernstein M.D., and Durst H.D. J. Am. Chem. Soc. 93 (1971) 2897
18. McNab H.J. Chem. Soc., Perkin Trans. 1: Org. & Bio-Org. Chem. 3 (1987) 653
19. Lanzilli G., Fuggetta M.P., Tricarico M., Cottarelli A., Serafino A., Falchetti R., Ravagnan G., Turriziani M., Adamo R., Franzese O., and Bonmassar E. Int. J. Oncol. 28 (2006) 641
20. Deng R., Zhong J., Dong Z., Wang J., Ding D., Shi Y., Wang S., Yang J., Guo B., and Gao X. Yaoxue Xuebao 19 (1984) 343 (NMR spectral data are not reported)